AstraZeneca Employees Detained in China Over Alleged Data, Drug-Import Violations — Update
By Helena Smolak
AstraZeneca said Chinese authorities detained some of its employees in Shenzhen for alleged violations of data-privacy laws and importing an unapproved cancer drug.
A spokesman for the drugmaker said five current and former employees were detained. The news was first reported by Bloomberg.
"We are aware a small number of our employees in China are under investigation and we have no further information to share at this point," a spokesman for the Anglo-Swedish pharma company said.
Shenzhen police didn't immediately respond to a request for comment.
AstraZeneca employs 16,000 staff in China out of 90,000 globally. China represented 13% of the company's revenue last year, making it the pharma major with the greatest sales exposure to the country, according to FactSet data.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
September 05, 2024 07:14 ET (11:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States